UNSPSC 51262001: Aceperone

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C24H29FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S69KXZ59AB, chemically known as acetamide, n-((1-(4-(4-fluorophenyl)-4-oxobutyl)-4-phenyl-4-piperidinyl)methyl)- (9ci) but generally known as aceperone, which bears US NIH Compound Identifier 13122. European Medicines Agency schedules Aceperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05212MIG.

UNSPSC 51262001 Aceperone is a Commodity code under which state and local governments procure emergency-response pharmaceuticals and controlled-substance management systems. Recent activity shows state and county health agencies buying naloxone (an opioid overdose reversal drug) and drug deactivation systems to support community health and public safety initiatives. Seminole County, Florida issued an IFB in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission posted an RFI in April 2026 exploring direct-to-manufacturer prescription fulfillment models and vendor capabilities for pharmacy benefit programs. The issuing bodies include county health departments and state health agencies; repeat buyers are not evident in the limited recent record. Vendors responding to these opportunities must meet standard state and local compliance requirements including E-Verify employment verification, drug-free workplace certification, workers' compensation and general liability insurance, and adherence to federal environmental regulations when FEMA funding is involved.

Recent activity concentrates in Florida and Texas. The Seminole County IFB (solicitation IFB60459723LAS, response due July 26, 2023) is representative of direct-purchase opportunities for naloxone and harm-reduction systems at the county level, with deliveries to a community health facility and pricing on a fixed-fee basis. The Texas HHS RFI (HHS0017013, posted April 3, 2026) signals state-level interest in restructuring pharmacy procurement through direct manufacturer relationships outside traditional PBM and GPO channels, though this remains an information-gathering phase without a formal competitive timeline or budget commitment. The code shows limited recent activity overall; opportunities are sparse and dispersed across jurisdictions, suggesting specialized demand driven by opioid-response policy rather than routine procurement volume.